April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Tailored Nanogels for Controlled Delivery of Therepeutics across Ocular Biological Barriers
Author Affiliations & Notes
  • T. L. Lowe
    Pharmaceutical Sciences, Thomas Jefferson University, Philadelphia, Pennsylvania
  • G. P. Misra
    Pharmaceutical Sciences, Thomas Jefferson University, Philadelphia, Pennsylvania
  • D. Daley
    College of Medicine,
    Pennsylvania State University, Hershey, Pennsylvania
  • H. Imai
    Ophthalmology,
    Pennsylvania State University, Hershey, Pennsylvania
  • R. Disantis
    College of Medicine,
    Pennsylvania State University, Hershey, Pennsylvania
  • T. W. Gardner
    Ophthalmology and Cellular & Molecular Physiology,
    Pennsylvania State University, Hershey, Pennsylvania
  • Footnotes
    Commercial Relationships  T.L. Lowe, None; G.P. Misra, None; D. Daley, None; H. Imai, None; R. Disantis, None; T.W. Gardner, None.
  • Footnotes
    Support  NIH, Wallace H. Coulter Foundation, JDRF
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2425. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. L. Lowe, G. P. Misra, D. Daley, H. Imai, R. Disantis, T. W. Gardner; Tailored Nanogels for Controlled Delivery of Therepeutics across Ocular Biological Barriers. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2425.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Many ocular therapeutics lack efficacy because of less efficient delivery due to ocular biological barriers. The present study aims at developing degradable nanogels with enhanced permeability for controlled release of therapeutics to the back of the eye.

Methods: : Nanogels, consisted of N-isopropylacrylamide and 2-hydroxyl methacrylate-lactide-dextran macromer, were synthesized in aqueous medium using UV photopolymerization under stirring. The size and morphology of the nanogels were studied by dynamic light scattering (DLS) and atomic force microscopy (AFM). Fluorescent-labeled insulin was loaded the nanogels during the synthesis process and released from the nanogels at solute concentration 2 mg/mL in phosphate buffered saline (PBS, pH 7.4) at 37 °C. Cytotoxicity of the nanogels to R28 and ARPE-19 retinal cells, and human brain microvessel endothelial cells (HBMVECs) was studied by a MTT cell viability assay. Permeability of the 100 µg/mL nanogels across the ARPE-19 and HBMVE monolayers was measured. Fluorescent-labeled nanogels were injected intravitreally and intravenously into Sprague-Dawley rats and their distribution in the retina, vitreous, cornea, and lens was assessed 1day later.

Results: : DLS and AFM data revealed that the size of the nanogels was around 70-90 nm. Nanogles released FITC-labeled insulin for 2 days in PBS at 37 °C. The nanogels were not cytotoxic to the R28 and ARPE-19 cells at concentration up to 1 mg/mL for at least one week. They were 10 and 5 folds more permeable than 4kDa dextran across the ARPE-19 and the HBMVEC monolayers, respectively. The fluorescent-labeled nanogels were detected in the retina but not in the cornea, lens, and vitreous after intravenous injection. In contrast, intravitreal injection indicated the presence of nanogels in the cornea and vitreous but not in the lens, and retina.

Conclusions: : The developed degradable nanogels are non-toxic and have potential to cross ocular biological barriers and deliver drugs to the retina.

Keywords: drug toxicity/drug effects • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×